CIRG (TRIO) 011/NSABP B-44-I / B020906: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab.

Trial Profile

CIRG (TRIO) 011/NSABP B-44-I / B020906: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Adenocarcinoma; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BETH
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Dec 2012 Planned end date changed from 1 Jun 2021 to 1 Dec 2021 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top